Merck & Co., Inc. (MRK) Stock

Healthcare · Drug Manufacturers - General · Member of S&P 500, Dow Jones

Merck & Co., Inc. (MRK) closed at USD 145.19 on 2026-10-15, a change of +72.6 % over the past year, with a market capitalization of USD 360.08B.

Merck & Co., Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Merck & Co., Inc. key figures

Previous close

USD 145.19 (2026-10-15)

1-year change

+72.6 %

Market cap

USD 360.08B

Enterprise value

USD 406.9B

P/E ratio (trailing)

115.83

P/E ratio (forward)

15.66

EPS (trailing)

1.26

EPS (forward)

9.32

PEG ratio

2.71

Price to book

8.59

Revenue growth

5.1 %

Earnings growth

n/a

Dividend per share (trailing)

3.32

Short ratio

2.88

Employees

73,000

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Merck & Co., Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Merck & Co., Inc. and compare it with other stocks.